5:14 PM
 | 
Feb 19, 2013
 |  BC Extra  |  Top Story

Gilead's sofosbuvir meets in fourth HCV trial

Gilead Sciences Inc. (NASDAQ:GILD) said once-daily sofosbuvir plus ribavirin given for 12 or 16 weeks each met the primary endpoint in the Phase III FUSION trial to treat chronic HCV genotype 2 and 3 infection in treatment-experienced patients who failed prior interferon-based therapy. Sofosbuvir significantly improved the proportion of patients who achieved a sustained virologic response...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >